Login to Your Account


Synthetic biology charges on with different strategies

By Brian Orelli
Staff Writer

Monday, December 5, 2016

The idea of synthetic biology – using computers, rather than trial and error, to rationally design drugs – has been around for years. But Woburn, Mass.-based Abpro is taking it to the next level with rationally designed antibodies using its Diversimmune platform. Labor intensive steps that used to take two to three years can now be done using bioinformatics that reduce the design time down to less than two months.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription